Document is current
Any future updates will be listed below
-
Authors
Philis-Tsimikas, Athena https://orcid.org/0000-0002-3986-9630
Krogsdahl Bache, Julie https://orcid.org/0000-0001-5764-1966
Fu, Ariel https://orcid.org/0009-0007-0220-5877
Kellerer, Monika https://orcid.org/0000-0002-9834-5976
Salvesen-Sykes, Karen https://orcid.org/0009-0000-1247-5650
Bain, Stephen C. https://orcid.org/0000-0001-8519-4964
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04460885 at ClinicalTrials.govnct04770532 at ClinicalTrials.govDocuments that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
https://doi.org/10.2337/dc20-2878
nct04795531 at ClinicalTrials.govDocuments that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
nct04880850 at ClinicalTrials.govDocuments that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
https://doi.org/10.2337/dc20-2878
nct04760626 at ClinicalTrials.govDocuments that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
nct04848480 at ClinicalTrials.govDocuments that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
https://doi.org/10.2337/dc20-2878
AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes
https://doi.org/10.1007/s13300-024-01679-3
Documents that mention this clinical trial
Insights on Hospitalisations from the Phase 3a ONWARDS 1–6 Trials of Once-Weekly Insulin Icodec
https://doi.org/10.1007/s13300-025-01745-4
New advances in type 1 diabetes
https://doi.org/10.1136/bmj-2023-075681
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 17 April 2025
First Online: 4 June 2025
Declarations
:
: Athena Philis-Tsimikas performs research and serves as an adviser on behalf of their employer for Abbott, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, and Sanofi; there has been no direct or indirect transfer of funds. Julie Krogsdahl Bache, Ariel Fu, and Karen Salvesen-Sykes are employees of Novo Nordisk and hold stock in Novo Nordisk. Monika Kellerer received honoraria for speaker’s bureau or advisory board attendance with Abbott Diabetes Care, AstraZeneca, Bayer AG, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, and Sanofi, and has also participated in randomised controlled trials funded by AstraZeneca, Eli Lilly, and Novo Nordisk. Stephen C. Bain received honoraria, teaching, and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, MSD, Novo Nordisk, Pfizer, Sanofi, and Takeda. Stephen C. Bain is an Editorial Board member of Diabetes Therapy. Stephen C. Bain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The ONWARDS 1–6 trials were conducted in compliance with the principles of the Declaration of Helsinki and in accordance with Good Clinical Practice guidelines of the International Conference on Harmonization [, ]. All relevant documents were reviewed and approved by the appropriate institutional review boards or independent ethics committees. All participants provided informed consent for participation in the trials and publication of data before enrolment. Further ethical approvals were not required for the present post hoc analysis, or de-identified case vignettes.
